A user-friendly, frequently updated reference guide that aligns with international guidelines and protocols.
Hereditary Spherocytosis and Other Membrane Abnormalities
Updated on: 10.05.25
Classification of protein abnormalities in the erythrocyte membrane that result in vertical or horizontal interaction defects and cause hemolytic anemia
Hereditary spherocytosis is an autosomal dominant condition, occurring due to defect in vertical interaction, characterized by abnormal shape and flexibility of RBCs.
Epidemiology:
Highest prevalence is seen in north European population (1 in 2000 births)
Etiology:
Mutation of genes encoding:
Ankyrin- ANK 1
Band 3- SLC4A1
Beta spectrin- SPTB1
Biallelic defects in band 4.2- EPB42
Biallelic defects in Alpha spectrin- SPTA1
Pathogenesis:
Deficiency of spectrin, ankyrin, band 3, protein 4.2 etc.
↓
Weakening of the vertical interaction
↓
Reduced membrane stability and spontaneous loss of cell membrane due to rapid vesciculation (process by which small, membrane-bound sacs i.e. vesicles are formed and bud off from the cell membrane)
↓
Reduction of cell surface to volume ratio
(Surface becomes less while volume remains same)
↓
RBC is forced to assume smallest possible diameter for a given volume i.e. sphere.
↓
As spherocytes have reduced flexibility, they are trapped in splenic sinusoids
↓
Extravascular hemolysis
Note:
Complete absence of spectrin is not viable, so homozygous children are not found.
Clinical severity depends on degree of spectrin deficiency
Classification:
Trait/ Carrier
Mild
Moderate
Severe
Hemoglobin (gm/dL)
Normal
11-15
8-12
6-8
Reticulocyte %
Normal
3-6
>6
>10
Bilirubin
<1.7
1.7-3.4
>3.4
>5.1
Spectrin molecules per RBC
100
80-100
50-80
40-60
Splenectomy
Not required
Usually not required
Necessary during school age, before puberty
Necessary at early age (Delay until 6 years if possible)
Clinical Features:
Varying presentation- Asymptomatic (compensated hemolysis) to marked hemolysis leading to hydrops fetalis. Severity depends on extent of loss of spectrin. Severity is relatively uniform in a given family.
Anemia- usually 5-30 days after birth as functioning of spleen becomes mature only after birth. But diagnosis may be made at any age depending on severity.
Splenomegaly- mild to moderate, may manifest with early satiety or left upper quadrant fullness.
Gall stones- Pigmented type
Acholuric jaundice- Jaundice with absence of bile in urine. Usually present since birth.
Family history: Found in 75% cases
3 types of crisis may be seen in hereditary spherocytosis
Hyperhemolytic crisis
Triggered by infection
Presents with fever, abdominal pain, splenic enlargement, Jaundice, hypotension and shock
Aplastic crisis
Triggered by parvovirus, trauma, surgery, pregnancy
Presents as sudden worsening anemia
Megaloblastic crisis
Occurs due to acquired folic acid deficiency, usually in high demand situations such as pregnancy.
Skin lesions- Leg ulcers, gouty tophi, chronic leg dermatitis, (related to decreased RBC deformability)
Extramedullary erythropoiesis- Masses may form in spine, kidney etc
Poor growth, deformities of hands and skull
Predisposition to malignancy- MPN, myeloma etc
Iron overload- May be seen even in untransfused patients due to associated HFE mutation (Ferritin >500mg/l and transferin saturation of >60% indicates iron overload)
Angioid streaks in optic fundi
Venous thromboembolism and pulmonary hypertension
Rare non-hematological manifestations:
Neuromuscular abnormalities (as ankyrin and spectrin are expressed in neural tissues)-slowly progressive spinocerebellar degenerative disease, spinal cord dysfunction, movement disorders, cardiomyopathy
Distal renal tubular acidosis is seen with defects with band 3.
Investigations:
(Findings are not very typical in newborns except high MCHC, hence better to rescheduled until the sixth month of age or later)
Hemogram:
Hemoglobin content- Normal/decreased
High quality smears are needed as spherocytes may appear as artifacts
Spherocytes- Abnormally small in sized RBCs which have uniform shape and lack central 1/3rd of pallor
Polychromatophilic cells and nucleated RBCs may be seen.
Pincered erythrocytes are seen in Band 3 deficiency.
Spherocytic acanthocytes are seen in beta spectrin deficiency
Spherocytes and stomatocytes may be seen in Japanese protein 4.2 deficiency
MCV- Normal/decreased
MCH – Normal
MCHC – Increased due to cellular dehydration (>36g/dL)- It is the only anemia where MCHC is increased. Laser based counters provide histograms with hyperdense erythrocytes (MCHC >40) which detects all cases of HS. Hence it is a best screening tool.
RDW- <14%
HS ratio- MCHC/MCV- If more than 0.36, it indicates presence of HS.
WBC and platelets – Normal
Reticulocyte count- >8%
Mean reticulocyte volume: Decreased
Reticulocyte count/ immature reticulocyte fraction ratio: Mild cases: More than 19 and severe cases More than 7.7.
Osmotic fragility test
Increased fragility
Hemolysis is complete between 0.5-0.4% NaCl
Normal test does not rule out HS.
False negative test is found in newborns due to the high level of fetal hemoglobin
Positive test is also seen in hereditary elliptocytosis, and autoimmune hemolytic anemia
Osmotic gradient ektacytometry- Measures deformability of whole RBC
Serum bilirubin-Raised (Mostly indirect)
Fecal urobilinogen- Raised
LDH – Raised
Haptoglobin-Decreased
DCT and ICT- Negative (needed, as spherocytes are seen in AIHA as well)
Peripheral smear of family members for HS
Autohemolysis test
It has value in differentiating various types of congenital nonspherocytic hemolytic anemias
It measures the degree of spontaneous hemolysis of blood incubated at 37o C
Degree of hemolysis depends on integrity of cell membrane & adequacy of cell enzymes involved in glycolysis.
Normal – 0.2 – 2% hemolysis after 24- 48 hours.
Abnormalities
Type
Observation
Seen in
Type I
2-6% auto hemolysis, but significant correction when glucose is added
PNH and G6PD deficiency
Type II
8-44% hemolysis& glucose has no effect
Pyruvate kinase deficiency
Type – III
5-25% hemolysis at 24 hours & 75% at 48 hrs
If glucose is added before incubation hemolysis is significantly reduced
Hereditory spherocytosis
Cryohemolysis test:
HS RBCs have a high susceptibility for lysis when rapidly cooled from 37 degree C to 0 degree celcius.
Acidified glycerol lysis test
Glycerol slows down entry of water into cells in vitro.
The time taken for lysis to occur is a function of the osmotic resistance of the cells
Hereditory spherocytosis cells lyses more rapidly than normal cells
Test is easier to perform than osmotic fragility test.
Sodium dodecylsulphate solubilized polyacrylamide gel (SDS-PAGE) electrophoresis
Used to quantify proteins in the membrane of RBCs
This is the confirmatory test for HS.
Results are expressed as ratios of individual RBC membrane proteins to Band 3.
Done only in specialized diagnostic centres and is time-consuming
Flow cytometry:
Binding of eosin labeled maleimide (EMA binding test)
Cells deficient in band 3 fail to bind to EMA
Most accurate screening test, with a relatively short time-around-time, high sensitivity, economical, and feasible. It can be done even in patients who have been transfused.
Other conditions giving reduced fluorescence: South east asian ovalocytosis, Congenital dyserythropoietic anemia Type-II, Hereditary pyropoikilocytosis and Cryohydrocytosis
Interpretation (Based on grade of fluorescence):
Positive for HS- Fluorescence is > 21%
Negative- Fluorescence is < 16%
Equivocal- If between 16% and 21%
Identification of gene defects by NGS-
Involves sequencing of relevant genes to identify mutations in them.
Widely available, cost effective and highly reliable.
Criteria for diagnosis:
History (including family history) and clinical findings (splenomegaly) suggestive of HS.
Presence of spherocytes and reticulocytosis
Negative direct antiglobulin test
If diagnosis is equivocal/ otherwise also: Preferable to do genetic testing (by NGS) for specific genetic mutations.
Treatment:
Folic acid supplementation- Life long for moderate and severe HS.
Transfuse PRBCs as and when required
Severe neonatal jaundice:
Phototherapy +/- exchange transfusion
Some children may need transfusion support for almost a year due to inability to mount an adequate erythropoietic response. Erythropoietin may be used until age of 9 months.
Splenectomy:
Restores the life-span of red cells to normal and hence cures hemolysis & hyperbilirubinemia.
Should be done after 6 years of age except in patients with severe anemia
Dehydrated hereditary stomatocytosis is a contraindication for splenectomy, hence this must be ruled out.
Laporoscopic is more feasible and safe. Any splenunculi (accessory splenic tissue) must be removed to prevent recurrence of symptoms.
Routine postoperative thromboprophylaxis should be given for adults.
Vaccinations (Pneumococcus, Hemophiluc influenza type b and meningococcus) must be given before procedure.
Prophylactic penicillin must be given for several years.
Cholecystectomy may be performed at the same time, if there is cholelithiasis (even if asymptomatic).
Chelation therapy/ phlebotomies- if there is iron overload.
Counseling to potential parents regarding possibility of neonatal jaundice and need for exchange transfusion
Hereditary Elliptocytosis
(Hereditary Ovalocytosis)
Autosomal dominant condition
Gene affected is closely related to Rh locus on chromosome 1
Classification
Type of HE
Hemolysis
Erythrocyte Shape
Common HE
Variable; minimal to severe
Elliptocytes
Spherocytic HE
(hemolytic ovalocytosis)
Present
Spherocytes and fat elliptocytes
Southeast Asian ovalocytosis
(Stomatocytic HE Melanesian/ South east Asian ovalocytosis)
Mild or absent
Roundish elliptocytes that are also stomatocytic (Spoon shaped RBCs)- Oval cells with 1-2 longitudinal slits
Defect involves horizontal membrane protein interactions
Actin
Protein 4.1
Adductin
Glycophorin C
RBCs fail to recover their biconcave shape after they acquire elliptical shape in microcirculation where they are subjected to shear stress.
Clinical features
90% do not have hemolysis
Asymptomatic HE patients may experience hemolysis in association with infections, hypersplenism, Vitamin B12 deficiency or microangiopathic disorders.
Stomatocytic HE Melanesian/ South east Asian ovalocytosis children can present with neonatal jaundice, but hemolysis resolves by 3 years of age. Homozygous status results in hydrops fetalis.
Some can have chronic hemolysis
Investigations:
Hemogram
Hemoglobin: Usually >12g/dL
Prominent elliptocytosis: >25% RBCs & usually >60% (<25% are seen with megaloblastic anemia and iron deficiency anemia)
Pseudoelliptocytes (Artifacts during smear preparation)- They are seen only near the tail. Long axes of all pseudo elliptocytes are parallel.
Reticulocyte count – Mild elevation – >4%
In hemolytic hereditary elliptocytosis, lab findings due to hemolysis are seen
Osmotic fragility test- Abnormal only in severe HE
Treatment
Splenectomy for hemolytic variant (Otherwise no treatment is needed)
Note: Elliptocytes are resistant to malarial infection due to abnormal rigidity of membrane
Hereditary Pyropoikilocytosis
Autosomal recessive
Presents in infancy as severe hemolytic anemia with extreme poikilocytosis
Cells fragment when heated to 45o-46 o C (Normal – 50 o C)
They disintegrate when incubated at 37 o C for more than 6 hours.
Pathogenesis:
Mutant spectrin- Prevents self association of heterodimers of spectrins
↓
Disruption of membrane skeletal lattice & Membrane cell destabilization
↓
Erythrocyte fragmentation & poikilocytosis
Peripheral smear: Morphologic abnormalities of RBCs- Budding, fragments, microspherocytes, elliptocytestriangulocytes.
MCV – Decreased (25-55fL)
Auto hemolysis- Increased and not corrected by glucose.
Hereditary Stomatocytosis
Autosomal dominant condition
4 variants depending on intracellular sodium concentration (Normal- 5-10 mmol/l)
Disclaimer: Information provided on this website is only for medical education purposes and not intended as medical advice. Although authors have made every effort to provide up-to-date information, the recommendations should not be considered standard of care. Responsibility for patient care resides with the doctors on the basis of their professional license, experience, and knowledge of the individual patient. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse effects, please refer to the approved product label. Neither the authors nor publisher shall be liable or responsible for any loss or adverse effects allegedly arising from any information or suggestion on this website. This website is written for use of healthcare professionals only; hence person other than healthcare workers is advised to refrain from reading the content of this website.